



BSRBR-RA Event of Special Interest (ESI) TUBERCULOSIS

Study ID:

HRN:

Patient Initials:

Gender:

Date of Birth:

NHS Number:

Event Date:

Biologic/biosimilar at time of event:

Product Batch Number:

Event Details (please annotate with any additional information)

Site of infection:

Diagnosis based on:

Clinical signs and symptoms

Chest X-Ray / CT Scan

PCR

If yes, please specify sample: _____

Acid fast bacilli

If yes, please specify sample: _____

Histology

If yes, please specify sample: _____

Diagnosis confirmed by CULTURE? YES / NO (please circle)

If yes, please specify sample: _____

Pre-treatment screening measures performed on patient:

PPD results mm

IGRA Result (Quantiferon) Positive Indeterminate Negative

Chest X-Ray → Did this indicate latent TB? Yes No

Please note any **relevant** family history: _____

Country of birth: _____ No of years lived in UK: _____

Has the patient received TB prophylaxis? YES NO UNKNOWN

If yes please provide start date: _____ and end date: _____

Please indicate which medication:

Medication prescribed to treat **active** TB:

Do you believe there is a possibility that this adverse event was related to the biologic/biosimilar drug used to treat RA? Yes No Unknown

If **Yes** please confirm which drug: _____

What was the outcome of the event?

Resolved Not Resolved Resolved with sequelae Fatal

Form completed

By: _____

On: ____/____/____

Return ESI/s to: BSRBR-RA. The University of Manchester,
Unit 4 Rutherford House, 40 Pencroft Way, Manchester Science Park
Manchester, M15 6SZ. biologics.register@manchester.ac.uk